Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LNSR 
LENSAR Inc (LNSR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LNSR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 118.26% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 142.98M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 2 | Beta 0.49 | 52 Weeks Range 5.25 - 17.31 | Updated Date 10/15/2025 |
52 Weeks Range 5.25 - 17.31 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.49% | Operating Margin (TTM) -15.18% |
Management Effectiveness
Return on Assets (TTM) -7.19% | Return on Equity (TTM) -350.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 130372365 | Price to Sales(TTM) 2.45 |
Enterprise Value 130372365 | Price to Sales(TTM) 2.45 | ||
Enterprise Value to Revenue 2.23 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 11934784 | Shares Floating 8637800 |
Shares Outstanding 11934784 | Shares Floating 8637800 | ||
Percent Insiders 19.41 | Percent Institutions 47.89 |
Upturn AI SWOT
LENSAR Inc
Company Overview
History and Background
LENSAR, Inc. is a global medical technology company focused on developing and commercializing its next-generation femtosecond laser technology for refractive cataract surgery. Founded in 2004, LENSAR introduced its first laser system in 2010. The company has focused on improving the precision, efficiency, and safety of cataract surgery procedures through advanced laser technology.
Core Business Areas
- Femtosecond Laser Systems: Development, manufacturing, and commercialization of femtosecond laser systems used in refractive cataract surgery.
- Disposable Products: Sale of single-use disposable items (e.g., patient interfaces) required for each laser procedure.
- Service and Support: Providing service, maintenance, and support for installed laser systems.
Leadership and Structure
LENSAR is led by a management team with experience in medical technology and ophthalmology. The company has a typical corporate structure with departments for R&D, sales & marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- LENSAR Laser System: A femtosecond laser system used for refractive cataract surgery, providing precise incisions and lens fragmentation. Market share data is not readily available, but estimates place LENSAR as a smaller player compared to Alcon (ALC), Johnson & Johnson (JNJ), and Carl Zeiss Meditec (AFX.DE). Competitors include Alcon, Johnson & Johnson Vision, and Carl Zeiss Meditec.
Market Dynamics
Industry Overview
The ophthalmic surgical market is driven by an aging population and increasing prevalence of cataracts. Advances in laser technology are driving adoption of femtosecond laser-assisted cataract surgery (FLACS).
Positioning
LENSAR is positioned as a technology innovator in the FLACS market, focusing on precision and efficiency. They compete with larger, more established players with broader product portfolios.
Total Addressable Market (TAM)
The global ophthalmic surgical devices market is estimated to be tens of billions of dollars. LENSAR is positioned to capture a share of the FLACS segment, a smaller portion of the overall market.
Upturn SWOT Analysis
Strengths
- Advanced femtosecond laser technology
- Focus on precision and efficiency
- Innovative product development
Weaknesses
- Smaller market share compared to larger competitors
- Limited product portfolio
- Reliance on single product line
Opportunities
- Expanding adoption of FLACS
- Developing new applications for femtosecond laser technology
- Entering new geographic markets
Threats
- Competition from larger players with greater resources
- Pricing pressure
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- AFX.DE
Competitive Landscape
LENSAR has the advantage of innovative femtosecond laser technology, but the disadvantages of a smaller market share and limited product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would require an analysis of past financial statements and market data.
Future Projections: Future growth projections would require analyst estimates, which are not publicly available without access to specific financial data sources.
Recent Initiatives: Recent strategic initiatives would require a review of press releases, investor presentations, and company filings.
Summary
LENSAR Inc. is a relatively small player in the refractive cataract surgery market with innovative laser technology. Their competitive landscape is challenging because they face larger competitors. LENSAR needs to expand its product offerings and increase market share to achieve sustained growth. Financial performance must be watched closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LENSAR Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2020-10-02 | President, CEO & Director Mr. Nicholas T. Curtis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 140 | Website https://www.lensar.com |
Full time employees 140 | Website https://www.lensar.com | ||
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.